Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03878147
Other study ID # 2191
Secondary ID R01HD098027
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date March 30, 2020
Est. completion date December 23, 2025

Study information

Verified date March 2024
Source Michigan State University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators will use Brain Power Games or Village Builder, two different MSU-developed computer-based learning games for children on Tablets, as a neurocognitive "stress test" or medical "challenge" test, in order to evaluate brain/behavior functional integrity in HIV-affected children. This dual use of BPG is a key innovative feature. Each of the 5 core BPG games lasts 10 minutes and trains fine motor, monitoring/attention, visual/auditory working memory, spatial navigational learning. Village Builder (VB) uses similar graphics as BPG, but is a pro-social "world-building" game where children gather and protect resources to build a village. thus VB emphasizes planning/reasoning (executive function or EF) neurocognitive abilities, while BPG emphasizes attention, memory, and learning tasks. In As an African child plays with BPG or VB on a touch-screen tablet, we will use games as a dynamic window into the child's developing brain and EF-based frontal lobe development Aim 1. Evaluate concurrent and predictive validity of BPG static (baseline) and dynamic (during 12 training sessions) cognitive assessments Aim 2. Compare the validity of BPG static and dynamic assessments Aim 3. Test the sensitivity of dynamic assessment to learning loss over time by evaluating how much BPG and/or VB performance gains diminish during a 6-month absence of training The investigator's central hypothesis is that the BPG and VB performance gains (dynamic assessment) will explain the additional variation in the gold-standard measures at time points after static (baseline) assessment, and more effectively capture the effects of HIV/ARV exposure and treatment across HIV affected cohorts (HIV, HEU, HUU) of children in Uganda and Malawi.


Description:

In Phase I of the study we randomize equal numbers of each of three exposure groups of children (perinatally HIV infected, perinatally HIV-exposed but not infected, and unexposed/uninfected children) to one of two intervention arms. They are randomized to either the Brain Powered Games (BPG) intervention arm of 12 sessions of hour-long training (twice a day for several days weekly at the study clinic), or to the "wait-listed" arm of no BPG training sessions. In phase II of the protocol (after pretesting, 2 months of waiting followed by post-training testing and then 6-month follow-up testing for both immediate and wait-listed BPG training arms - the wait-listed children will all undergo 12 sessions of village Builder which is a pro-social reasoning/planning strategy game newly developed by our Games for Entertainment and Learning (GEL) lab at Michigan State University (MSU). In Phase II for the Village Builder children, all children will also undergo neuropsychological testing before and after the 12 training sessions, as well as neuropsychological assessment at six-month follow-up post training.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 600
Est. completion date December 23, 2025
Est. primary completion date February 29, 2024
Accepts healthy volunteers No
Gender All
Age group 5 Years to 12 Years
Eligibility Inclusion Criteria: - HEU and HUU children at least 5 yrs of age and older from the PROMISE ND study (Uganda and Malawi) - HIV+ children from P1104s (Uganda and Malawi) - HUU children age-matched from PROMISE ND and P1104s study cohorts (Uganda and Malawi) Exclusion Criteria: - Medical history of serious birth complications - Severe malnutrition - Bacterial meningitis - Encephalitis - Cerebral malaria - Other known brain injury or disorder requiring hospitalization - Seizures or other neurological disabilities

Study Design


Intervention

Behavioral:
Cognitive Games Training
Brain Powered Games (BPG) uses games for neurocognitive assessment and training, using images and sounds more familiar to African children. As a computerized cognitive rehabilitation training (CCRT) program designed for Sub-Saharan African school-age children, it can help children infected affected directly or indirectly by HIV. BPG consists of 5 core games evaluating different cognitive abilities (learning, memory, language, attention). Each game includes a visual tutorial, several adjustable settings on the administrative side (Admin), and records game play data for research purposes. Village Builder (VB) is a pro-social reasoning/planning world building strategy type game intended to evaluate frontal lobe executive functions in a culture-friendly and enjoyable game manner. It consists of many of the village artistic components as used in BPG but orchestrated into a village setting where children must gather resources and protect them in order to expand the capacity of the village.

Locations

Country Name City State
Malawi Johns Hopkins Research Project Blantyre
Uganda Makerere University Johns Hopkins University Research Collaboration Kampala

Sponsors (6)

Lead Sponsor Collaborator
Michigan State University Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Johns Hopkins University, Kamuzu University of Health Sciences, MU-JHU CARE, University of Michigan

Countries where clinical trial is conducted

Malawi,  Uganda, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Kaufman Assessment Battery for Children 2nd Ed (KABC-II) scores the KABC-II will be the principal test for cognitive ability.47 It is validated in sub-Saharan Africa48-51 and has been adapted for pediatric HIV research.1,18,46,52-55 Using the Luria model for neuropsychological assessment within KABC-II, the primary outcome variables are the global scores of Sequential Processing (memory), Simultaneous Processing (visual-spatial processing and problem solving), Learning (immediate and delayed memory), Planning (executive reasoning), Delayed Recall, Nonverbal Index (NVI) subtests not dependent on understanding instructions in English, and Mental Processing Index (MPI), a composite of all the cognitive performance areas. Baseline, 3 months, and 6 months follow-up
Secondary Change in Test of Variables of Attention (TOVA) scores TOVA is a computerized visual continuous performance test used in to screen, diagnose and monitor children and adults at risk for ADHD.56 TOVA consists of the rapid (tachistoscopic) presentation of a large geometric square on the computer screen with a smaller dark box either in the upper position (signal) or lower position (non-signal). The child is asked to press a switch held in the preferred hand as fast as possible in response to the signal (measuring vigilance attention), but to withhold responding to the non-signal (measuring impulsivity). Baseline, 3 months, and 6 months follow-up
Secondary Change in CogState scores CogState presents a 30-min session that includes playing cards in a game-like manner to assess memory, attention, discrimination learning, and executive function that is non-language dependent. CogState tests include Card Detection (simple reaction time), Identification (choice reaction time), One-Back Working Memory, and One-Card Learning. CogState also includes the Groton Maze Task, which can measure visual-motor tracking (Maze Chase) and executive functioning/planning (Maze Learning). Baseline, 3 months, and 6 months follow-up
Secondary Change in Achenbach Child Behavior Checklist (CBCL) scores Parent-based screening tool for emotional and behavioral problems observed in the child. CBCL is important to assess when a child's social environment is enriched by adult oversight in game assessment and training, reflecting a collateral training benefit Baseline, 3 months, and 6 months follow-up
Secondary Change in Caldwell Home Observation for the Measurement of the Environment (HOME) scores We will use the middle childhood version of the Caldwell Home Observation for the Measurement of the Environment (HOME) validated for use as an important distal measure predictive of our gold standard assessments.The HOME assesses the stimulation and learning opportunities offered by the child's home environment. Baseline, 3 months, and 6 months follow-up
Secondary Change inCD4+ T-cell counts (HIV cohort only) As part of their standard of care (HIV cohort only), CD4 measures will be available from a blood draw taken within a week from the time of neuropsychological assessment as a more proximal predictor of disease effects on assessment performance Baseline, 3 months, and 6 months follow-up
Secondary Change in viral load (HIV cohort only) As part of their standard of care (HIV cohort only), viral load will be available from a blood draw taken within a week from the time of neuropsychological assessment as a more proximal predictor of disease effects on assessment performance Baseline, 3 months, and 6 months follow-up
Secondary Change in CD8 cell count (HIV cohort only) As part of their standard of care (HIV cohort only), CD8 measures will be available from a blood draw taken within a week from the time of neuropsychological assessment as a more proximal predictor of disease effects on assessment performance Baseline, 3 months, and 6 months follow-up
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2